Fitzgrald

46

### RAW SEQUENCE LISTING PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:04

INPUT SET: S30362.raw

This Raw Listing contains the General Information Section and up to the first 5 pages.

| 1<br>2                                 |        | SEQUENCE LISTING ENTERED  |
|--|--------|---|
| 3                                      | (1) Ge | eneral Information:   |
| 4                                      | (1) Ge | meral infoliacion.  |
| 5<br>6                                 | (i)    | APPLICANT: Lee, Jong Y.   |
| 7<br>8<br>9                            | (ii)   | TITLE OF INVENTION: PURIFIED HUMAN ERYTHROPOIETIN RECEPTOR PROTEIN FRAGMENT AND ANTIBODIES DERIVED THEREFROM  |
| 10<br>11                               | (iii)  | NUMBER OF SEQUENCES: 5  |
| 12<br>13<br>14<br>15<br>16<br>17<br>18 | (iv)   | CORRESPONDENCE ADDRESS:  (A) ADDRESSEE: Fish & Richardson P.C., P.A.  (B) STREET: 60 South Sixth Street, Suite 3300  (C) CITY: Minneapolis  (D) STATE: MN  (E) COUNTRY: USA  (F) ZIP: 55402 |
| 20<br>21<br>22<br>23<br>24<br>25       | (v)    | COMPUTER READABLE FORM:  (A) MEDIUM TYPE: Floppy disk  (B) COMPUTER: IBM compatible  (C) OPERATING SYSTEM: DOS  (D) SOFTWARE: FastSEQ for Windows Version 2.0                               |
| 26<br>27<br>28<br>29                   | (vi)   | CURRENT APPLICATION DATA:  (A) APPLICATION NUMBER: 09/016,159  (B) FILING DATE: 30-JAN-1998   |
| 30<br>31<br>32<br>33                   | (vi)   | PRIOR APPLICATION DATA:  (A) APPLICATION NUMBER: 08/876,227  (B) FILING DATE: 16-JUN-1997   |
| 34<br>35<br>36<br>37                   | (vi)   | PRIOR APPLICATION DATA:  (A) APPLICATION NUMBER: 08/734,097  (B) FILING DATE: 21-OCT-1996   |
| 38<br>39<br>40<br>41                   | (vi)   | PRIOR APPLICATION DATA:  (A) APPLICATION NUMBER: 08/460,525  (B) FILING DATE: 02-JUN-1995   |
| 42<br>43<br>44<br>45                   | (viii) | ATTORNEY/AGENT INFORMATION: (A) NAME: Ellinger, Mark S. (B) REGISTRATION NUMBER: 34,812 (C) REFERENCE/DOCKET NUMBER: 07004/002003   |

# RAW SEQUENCE LISTING PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:04

INPUT SET: S30362.raw

|                            |           | 11.11 C1 5251. 5000021.417   |
|----------------------------|-----------|--|
| 47<br>48<br>49<br>50       | (ix)      | TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 612/335-5070 (B) TELEFAX: 612/288-9696   |
| 52<br>53                   | (2) INFO  | RMATION FOR SEQ ID NO:1:   |
| 54<br>55<br>56             | (i)       | SEQUENCE CHARACTERISTICS:  (A) LENGTH: 23 base pairs  (B) TYPE: nucleic acid   |
| 57<br>58<br>59             |           | (C) STRANDEDNESS: single (D) TOPOLOGY: linear  |
| 60<br>61                   | (ii)      | MOLECULE TYPE: synthetic DNA   |
| 62<br>63                   | (iii)     | HYPOTHETICAL: NO   |
| 64<br>65<br>66             | (iv)      | ANTI-SENSE: NO   |
| 67<br>68                   | (ix)      | FEATURE: (A) NAME/KEY: BamH1 linker ar 5' end followed by sequence for amino   |
| 69<br>70<br>71<br>72       |           | through 29 of the full length human Epor protein. Forward primer for ID No. 2."  |
| 72<br>73<br>74             | (xi)      | SEQUENCE DESCRIPTION: SEQ ID NO:1:   |
| 75<br>76<br>77<br>78       | TTGGATCC  | GCG CCC CCG CCT A AC 23 Ala Pro Pro Pro 1  |
| 79<br>80                   | (2) INFO  | RMATION FOR SEQ ID NO:2:   |
| 81<br>82<br>83<br>84<br>85 | (i)       | SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear |
| 87<br>88                   | (ii)      | MOLECULE TYPE: synthetic DNA   |
| 89<br>90                   | (iii)     | HYPOTHETICAL: NO   |
| 91<br>92<br>93             | (iv)      | ANTI-SENSE: NO   |
| 94<br>95                   |           | FEATURE: (A) NAME/KEY: EcoR1 linker followed by sequence complementary to  |
| 96<br>97<br>98             | coding se | equence for amino acids 226 through 222 of full length human EpoR<br>Reverse primer for Sequence ID No. 1.                   |

99

# RAW SEQUENCE LISTING PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:05

#### INPUT SET: \$30362.raw

|            |          | 11,1 01 5511 50000   |       |
|------------|----------|--|-------|
| 100<br>101 | (xi)     | SEQUENCE DESCRIPTION: SEQ ID NO:2:                             |       |
| 102        | TGAATTCG | GG GTCCAGGTCG CT   | 22    |
| 103        |          |  |       |
| 104<br>105 | (2) INFO | RMATION FOR SEQ ID NO:3:                                       |       |
| 106        | (i)      | SEQUENCE CHARACTERISTICS:                                      |       |
| 107        | (-/      | (A) LENGTH: 18 base pairs                                      |       |
| 108        |          | (B) TYPE: nucleic acid   |       |
| 109        |          | (C) STRANDEDNESS: double                                       |       |
| 110        |          | (D) TOPOLOGY: linear   |       |
| 111        |          | (2) 10101011 111001  |       |
| 112        | (ii)     | MOLECULE TYPE: other nucleic acid                              |       |
| 113        | (11)     | NOLLOWLE TITE. COMOL MACIOTO WOLK                              |       |
| 114        | (iii)    | HYPOTHETICAL: NO   |       |
| 115        | (+++)    | 111011111111111  |       |
| 116        | (iv)     | ANTI-SENSE: NO   |       |
| 117        | (= , ,   |  |       |
| 118        | (vi)     | ORIGINAL SOURCE:   |       |
| 119        | ( - /    | (A) ORGANISM: Homo sapiens                                     |       |
| 120        |          | (cs) constants memor captures                                  |       |
| 121        | (vii)    | IMMEDIATE SOURCE:  |       |
| 122        | ( 7      | (B) CLONE: pGEX-2T, Pharmacia (Mechanicsburg, PA)              |       |
| 123        |          | (a) (a) (a) (b) (b) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c |       |
| 124        | (ix)     | FEATURE:   |       |
| 125        | ` '      | (A) NAME/KEY: Thrombin Cleavage Site in plasmid vector pGEX    | -2T." |
| 126        |          |  |       |
| 127        | (x)      | PUBLICATION INFORMATION:                                       |       |
| 128        | . ,      | (A) AUTHORS: Smith, D.B.                                       |       |
| 129        |          | Johnson, K.S.  |       |
| 130        |          | (B) TITLE: Single-step purification of polypeptides            |       |
| 131        |          | expressed in Escherichia coli as fusions with                  |       |
| 132        |          | glutathione-S-transferase                                      |       |
| 133        |          | (D) VOLUME: 67   |       |
| 134        |          | (F) PAGES: 31-40   |       |
| 135        |          | (G) DATE: 1988   |       |
| 136        |          |  |       |
| 137        | (xi)     | SEQUENCE DESCRIPTION: SEQ ID NO:3:                             |       |
| 138        |          |  |       |
| 139        | CTG GTT  | CCG CGT GGA T CC   | 18    |
| 140        | Leu Val  | Pro Arg Gly  |       |
| 141        | 5        |  |       |
| 142        |          |  |       |
| 143        | (2) INFO | RMATION FOR SEQ ID NO:4:                                       |       |
| 144        |          |  |       |
| 145        | (i)      | SEQUENCE CHARACTERISTICS:                                      |       |
| 146        |          | (A) LENGTH: 1527 base pairs                                    |       |
| 147        |          | (B) TYPE: nucleic acid   |       |
| 148        |          | (C) STRANDEDNESS: double                                       |       |
| 149        |          | (D) TOPOLOGY: linear   |       |
| 150        |          |  |       |
| 151        |          |  |       |
| 152        | (x)      | PUBLICATION INFORMATION:                                       |       |

### RAW SEQUENCE LISTING PATENT APPLICATION US/09/016,159

TIME: 15:14:05

DATE: 01/27/1999

#### INPUT SET: S30362.raw

|     |                                    |            |       |      |      |      |      |      |             |      |      |     | IN  | PUT S | ET: S | 80362.raw |
|-----|------------------------------------|------------|-------|------|------|------|------|------|-------------|------|------|-----|-----|-------|-------|-----------|
| 153 |                                    | ( A        | L) AU | THOR | S: W | inke | lman | n ,  | J. C        | ., e | t al |     |     |       |       |           |
| 154 |                                    | (0         | :) JO | URNA | L: B | lood |      |      |             |      |      |     |     |       |       |           |
| 155 |                                    | (I         | ) vo  | LUME | : 76 |      |      |      |             |      |      |     |     |       |       |           |
| 156 | (E) ISSUE: 1                       |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 157 |                                    | ( F        | ') PA | GES: | 24-  | 30   |      |      |             |      |      |     |     |       |       |           |
| 158 |                                    | (G         | ;) DA | TE:  | 1990 |      |      |      |             |      |      |     |     |       |       |           |
| 159 | (x                                 | ) PUE      |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 160 |                                    | ( <b>A</b> | AU (A | THOR | S: J | ones | , S. | S.,  | et a        | 1.   |      |     |     |       |       |           |
| 161 |                                    | (0         | :) JO | URNA | L: B | lood |      |      |             |      |      |     |     |       |       |           |
| 162 |                                    | (r         | ) vo  | LUME | : 76 |      |      |      |             |      |      |     |     |       |       |           |
| 163 |                                    | (E         | ) IS  | SUE: | 1    |      |      |      |             |      |      |     |     |       |       |           |
| 164 |                                    | ( F        | ') PA | GES: | 31-  | 35   |      |      |             |      |      |     |     |       |       |           |
| 165 |                                    | (G         | ) DA  | TE:  | 1990 |      |      |      |             |      |      |     |     |       |       |           |
| 166 | (x) PUBLICATION INFORMATION:       |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 167 | (A) AUTHORS: Noguchi, C.T., et al. |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 168 | (C) JOURNAL: Blood                 |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 169 |                                    | (I         | ) VO  | LUME | : 78 |      |      |      |             |      |      |     |     |       |       |           |
| 170 |                                    | (E         | ) IS  | SUE: | 10   |      |      |      |             |      |      |     |     |       |       |           |
| 171 |                                    | (F         | ') PA | GES: | 254  | 8-25 | 56   |      |             |      |      |     |     |       |       |           |
| 172 |                                    | (G         | ) DA  | TE:  | 1991 |      |      |      |             |      |      |     |     |       |       |           |
| 173 |                                    |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 174 | (xi                                | ) SEQ      | UENC  | E DE | SCRI | PTIO | N: S | EQ I | D NO        | :4:  |      |     |     |       |       |           |
| 175 |                                    |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 176 | ATG GA                             | C CAC      | CTC   | GGG  | GCG  | TCC  | CTC  | TGG  | CCC         | CAG  | GTC  | GGC | TCC | CTT   | TGT   | 48        |
| 177 | Met As                             | p His      | Leu   | Gly  | Ala  | Ser  | Leu  | Trp  | Pro         | Gln  | Val  | Gly | Ser | Leu   | Cys   |           |
| 178 | 1                                  |            |       | 5    |      |      |      |      | 10          |      |      |     |     | 15    |       |           |
| 179 |                                    |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 180 | CTC CT                             | G CTC      | GCT   | GGG  | GCC  | GCC  | TGG  | GCG  | CCC         | CCG  | CCT  | AAC | CTC | CCG   | GAC   | 96        |
| 181 | Leu Le                             | u Leu      | Ala   | Gly  | Ala  | Ala  | Trp  | Ala  | Pro         | Pro  | Pro  | Asn | Leu | Pro   | Asp   |           |
| 182 |                                    |            | 20    | _    |      |      | _    | 25   |             |      |      |     | 30  |       | _     |           |
| 183 |                                    |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 184 | CCC AA                             | G TTC      | GAG   | AGC  | AAA  | GCG  | GCC  | TTG  | CTG         | GCG  | GCC  | CGG | GGG | CCC   | GAA   | 144       |
| 185 | Pro Ly                             | s Phe      | Glu   | Ser  | Lys  | Ala  | Ala  | Leu  | Leu         | Ala  | Ala  | Arg | Gly | Pro   | Glu   |           |
| 186 |                                    | 35         |       |      |      |      | 40   |      |             |      |      | 45  |     |       |       |           |
| 187 |                                    |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 188 | GAG CT                             | r ctg      | TGC   | TTC  | ACC  | GAG  | CGG  | TTG  | GAG         | GAC  | TTG  | GTG | TGT | TTC   | TGG   | 192       |
| 189 | Glu Le                             | u Leu      | Cys   | Phe  | Thr  | Glu  | Arg  | Leu  | Glu         | Asp  | Leu  | Val | Cys | Phe   | Trp   |           |
| 190 | 50                                 |            |       |      |      | 55   | •    |      |             |      | 60   |     |     |       |       |           |
| 191 |                                    |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 192 | GAG GA                             |            |       |      |      |      |      |      |             |      |      |     |     |       |       | 240       |
| 193 | Glu Gl                             | u Ala      | Ala   | Ser  | Ala  | Gly  | Val  | Gly  | Pro         | Gly  | Asn  | Tyr | Ser | Phe   | Ser   |           |
| 194 | 65                                 |            |       |      | 70   |      |      |      |             | 75   |      |     |     |       | 80    |           |
| 195 |                                    |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 196 | TAC CA                             | G CTC      | GAG   | GAT  | GAG  | CCA  | TGG  | AAG  | CTG         | TGT  | CGC  | CTG | CAC | CAG   | GCT   | 288       |
| 197 | Tyr Gl                             | n Leu      | Glu   | Asp  | Glu  | Pro  | Trp  | Lys  | Leu         | Cys  | Arg  | Leu | His | Gln   | Ala   |           |
| 198 |                                    |            |       | 85   |      |      |      |      | 90          |      |      |     |     | 95    |       |           |
| 199 |                                    |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 200 | CCC AC                             |            |       |      |      |      |      |      |             |      |      |     |     |       |       | 336       |
| 201 | Pro Th                             | r Ala      | Arg   | Gly  | Ala  | Val  | Arg  | Phe  | ${\tt Trp}$ | Cys  | Ser  | Leu | Pro | Thr   | Ala   |           |
| 202 |                                    |            | 100   |      |      |      |      | 105  |             |      |      |     | 110 |       |       |           |
| 203 |                                    |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |
| 204 | GAC AC                             |            |       |      |      |      |      |      |             |      |      |     |     |       |       | 384       |
| 205 | Asp Th                             | r Ser      | Ser   | Phe  | Val  | Pro  | Leu  | Glu  | Leu         | Arg  | Val  | Thr | Ala | Ala   | Ser   |           |
|     |                                    |            |       |      |      |      |      |      |             |      |      |     |     |       |       |           |

PAGE: 5

# RAW SEQUENCE LISTING PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:05

|     |        |            |     |     |     |       |     |     |     |     |      |              |     | INPUT SET: S30362.raw |      |       |      |
|-----|--------|------------|-----|-----|-----|-------|-----|-----|-----|-----|------|--------------|-----|-----------------------|------|-------|------|
| 206 |        |            | 115 |     |     |       |     | 120 |     |     |      |              | 125 |                       |      |       |      |
| 207 |        |            |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |
| 208 | GGC    | GCT        | CCG | CGA | TAT | CAC   | CGT | GTC | ATC | CAC | ATC  | AAT          | GAA | GTA                   | GTG  | CTC   | 432  |
| 209 |        | Ala        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |
| 210 | 2      | 130        |     |     | 4 - |       | 135 |     |     |     |      | 140          |     |                       |      |       |      |
| 211 |        |            |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |
| 212 | СТА    | GAC        | GCC | כככ | GTG | GGG   | СТС | GTG | GCG | CGG | ттс  | ССТ          | GAC | GAG                   | AGC  | GGC   | 480  |
| 213 |        | Asp        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |
| 214 | 145    | 1101       |     |     |     | 150   |     |     |     | 9   | 155  |              |     |                       |      | 160   |      |
| 215 | -10    |            |     |     |     | 130   |     |     |     |     | -55  |              |     |                       |      | 100   |      |
| 216 | CAC    | GTA        | CTC | ጥጥር | CCC | тсс   | CTC | CCG | CCG | ССТ | GAG  | מכמ          | CCC | ΔТС                   | ACG  | ጥርጥ   | 528  |
| 217 |        | Val        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       | 320  |
| 218 | HIS    | val        | var | пец | 165 | rrp   | пец | FIO | FIC | 170 | GIU  | 1111         | FIU | Mec                   | 175  | DCI   |      |
| 219 |        |            |     |     | 165 |       |     |     |     | 170 |      |              |     |                       | 1/3  |       |      |
| 220 | CAC    | ATC        | dád | TAC | CAC | CTC   | CAC | СТС | TCC | CCC | aaa  | אאכי         | ccc | CCA                   | ccc  | N.C.C | 576  |
| 221 |        |            |     |     |     |       |     |     |     |     |      |              |     |                       |      |       | 576  |
|     | птъ    | Ile        | ALG | _   | GIU | vai   | Asp | vai |     | нта | GIY  | ASII         | СТУ | 190                   | GIY  | per   |      |
| 222 |        |            |     | 180 |     |       |     |     | 185 |     |      |              |     | 190                   |      |       |      |
| 223 | CITI N | <b>a</b> a | 200 | ama | 030 | 3 000 | аша | 070 | aaa | aaa | 3.00 | <b>a</b> a a | mam | ama                   | ama  | 700   | 624  |
| 224 |        | CAG        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       | 624  |
| 225 | vai    | Gln        | _   | vai | GIU | тте   | ьeu |     | GIY | Arg | Thr  | GIU          | -   | vai                   | Leu  | ser   |      |
| 226 |        |            | 195 |     |     |       |     | 200 |     |     |      |              | 205 |                       |      |       |      |
| 227 |        | ~~~        | ~~~ |     | ~~~ |       |     |     |     |     | ~~~  |              | ~=~ | ~~~                   | ~~=  |       | 670  |
| 228 |        | CTG        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       | 672  |
| 229 | Asn    | Leu        | Arg | GIA | Arg | unr   | _   | Tyr | Thr | Pne | Ата  |              | ьeu | Ата                   | Arg  | Met   |      |
| 230 |        | 210        |     |     |     |       | 215 |     |     |     |      | 220          |     |                       |      |       |      |
| 231 |        |            |     |     |     |       | ~~~ |     | _~~ |     |      |              |     | ~- ~                  | ~ ~~ | ~     | =    |
| 232 |        | GAG        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       | 720  |
| 233 |        | Glu        | Pro | Ser | Phe | _     | GIY | Phe | Trp | ser |      | Trp          | Ser | GIu                   | Pro  |       |      |
| 234 | 225    |            |     |     |     | 230   |     |     |     |     | 235  |              |     |                       |      | 240   |      |
| 235 |        |            |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |
| 236 |        | CTG        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       | 768  |
| 237 | Ser    | Leu        | Leu | Thr |     | Ser   | Asp | Leu | Asp |     | Leu  | Ile          | Leu | Thr                   |      | Ser   |      |
| 238 |        |            |     |     | 245 |       |     |     |     | 250 |      |              |     |                       | 255  |       |      |
| 239 |        |            |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |
| 240 |        | ATC        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       | 816  |
| 241 | Leu    | Ile        | Leu |     | Val | Ile   | Leu | Val |     | Leu | Thr  | Val          | Leu |                       | Leu  | Leu   |      |
| 242 |        |            |     | 260 |     |       |     |     | 265 |     |      |              |     | 270                   |      |       |      |
| 243 |        |            |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |
| 244 |        | CAC        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       | 864  |
| 245 | Ser    | His        | _   | _   |     |       |     |     |     |     |      |              |     |                       | Pro  | Ser   |      |
| 246 |        |            | 275 |     |     |       |     | 280 |     |     |      |              | 285 |                       |      |       |      |
| 247 |        |            |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |
| 248 |        | GAG        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       | 912  |
| 249 | Pro    | Glu        | Ser | Glu | Phe | Glu   | Gly | Leu | Phe | Thr | Thr  | His          | Lys | Gly                   | Asn  | Phe   |      |
| 250 |        | 290        |     |     |     |       | 295 |     |     |     |      | 300          |     |                       |      |       |      |
| 251 |        |            |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |
| 252 |        | CTG        |     |     |     |       |     |     |     |     |      |              |     |                       |      |       | 960  |
| 253 | Gln    | Leu        | Trp | Leu | Tyr | Gln   | Asn | Asp | Gly | Cys | Leu  | Trp          | Trp | Ser                   | Pro  | Cys   |      |
| 254 | 305    |            |     |     |     | 310   |     |     |     |     | 315  |              |     |                       |      | 320   |      |
| 255 |        |            |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |
| 256 | ACC    | CCC        | TTC | ACG | GAG | GAC   | CCA | CCT | GCT | TCC | CTG  | GAA          | GTC | CTC                   | TCA  | GAG   | 1008 |
| 257 | Thr    | Pro        | Phe | Thr | Glu | Asp   | Pro | Pro | Ala | Ser | Leu  | Glu          | Val | Leu                   | Ser  | Glu   |      |
| 258 |        |            |     |     | 325 |       |     |     |     | 330 |      |              |     |                       | 335  |       |      |
|     |        |            |     |     |     |       |     |     |     |     |      |              |     |                       |      |       |      |

PAGE: 1

# SEQUENCE VERIFICATION REPORT PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:06

INPUT SET: \$30362.raw

Line Error

Original Text

### ~ 11 . 4

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. §§ 1.821-1.825 for the following reason(s):

- [ ] 1. This application clearly fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990, and at 55 FR 18230, May 1, 1990.
- [X] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. § 1.821(c).
- [X] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. § 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. §§ 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing".
- [ ] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. § 1.825(d).
- [ ] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. § 1.821(e).

### [X] 7. Other:

A paper copy sequence listing was filed with the application. However, no computer-readable copy or request that the Office prepare such copy from the listing filed in the parent application (37 C.F.R. § 1.821(e)) was received. Additionally, no amendment directing entry of the sequence listing into the specification was submitted.

### Applicant must provide:

- [X] An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- [X] An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry of the sequence listing into the specification.
- [X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. § 1.821(e) or § 1.821(f) or § 1.821(g) or § 1.825(b) or § 1.825(d).

For questions regarding compliance with these requirements, please contact one of the following:

For rules interpretation, call (703) 308-4216.

For CRF submission help, call (703) 308-4212.

For PatentIn software help, call (703) 557-0400.

Please return a copy of this notice with your response.